FDA Investigator Wayne T Smith
Wayne T Smith has inspections in 8 countries as of 31 Aug 2023. Wayne T Smith has collaborated with a combined 2778 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
20
Last Inspection Date:
31 Aug 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
India,
China,
Italy,
Belgium,
Israel,
United States of America,
Netherlands,
United Kingdom of Great Britain and Northern Ireland
Co-Investigator(s):
Alan P Kurtzberg,
Albert A Salvador,
Alicia M Mozzachio,
Allan P Kurtzberg,
Allen F Hall,
Amanda E Lewin, PhD,
Anastasia M Shields,
Ann L Demarco,
Ann Marie Montemurro,
Anna M Brannen,
Anthony A Charity,
Anthony C Warchut,
Barbara Janine Breithaupt,
Ben Du,
Bonita S Chester,
Brandy N Lepage,
Charles I Ann,
Charles R Cote, RIC,
Christian D Lynch (CDL),
Christina K Theodorou,
Christina Theodorou,
Christopher T Middendorf,
Concepcion Cruz, Jr,
Craig D Zagata,
Cynthia J Lee, MS,
Cynthia White,
Daniel J Grabicki,
Daniel T Lee,
David R Heiar,
Debra J Bennett,
Debra L Pagano,
Demitria J Xiradakis,
Dennis Cantellops Paite,
Derek S Dealy,
Derek S Smith, PhD,
Dipesh K Shah,
Douglas A Campbell,
Dr. Barbara D Paul, PhD,
Dr. Robert C Horan, MD,
Elena Karnaukhova, PhD,
Eric M Mueller, PharmD,
Erika M Wilkerson,
Farhana Khan,
Felix Maldonado,
Frank W Perrella,
Gajendiran Mahadevan, PhD,
Gayle S Lawson,
George J Flynn,
Gerardo Z Vazquez,
Hala L Selby,
Hanisol Fabenelle,
Jacqueline Mdiaz Albertini,
James C Maclaughlin,
James D Planchon,
Jeen S Min,
John S Hartford,
Jorge L Guadalupe,
Jose Acruz Gonzalez,
Jose Alopez Rubet,
Jose R Hernandez,
Jose Velez,
Judith A Paterson,
Julianne C Mccullough,
Kara A Scheibner, PhD,
Karen E D'orazio,
Katherine E Jacobitz,
Katherine Szestypalow,
Kathryn A Krentz,
Kevin A Gonzalez,
Kham Phommachanh,
Kimberley A Hoefen,
Kirtida Patel,
Kristina J Donohue,
Latorie S Jones,
Laurie B Frazier,
Leonard H Lavi,
Linda Thai,
Lisa L Tung,
LTJG Bradley E Benasutti,
Luis M Burgos Medero,
Marc R Dickens,
Marcelo O Mangalindan, Jr,
Margaret A Smithers,
Margaret M Annes,
Maridalia Torres Irizarry,
Marie F Morin,
Marisol Faberlle,
Martha Sullivan Myrick,
Marvin D Jones,
Matthew B Casale,
Meena Bansal Gupta, PhD,
Michael D Omeara,
Michael S Araneta,
Mike M Rashti,
Mohsen Rajabi Abhari, FDA,
Mra Davism,
Mra M Barbosar,
Mra Mcculloughj,
Muralidhara B Gavini, PhD,
Murthy Vkn Sikha,
Nadeem I Chaudhry,
Nicole K Trudel,
Norman K Starks,
Patrick L Wisor,
Paul L Bellamy,
Peter E Baker,
Pratik S Upadhyay, DDC,
Rafael E Arroyo,
Reba A Gates,
Regina T Brown,
Reyes Candau Chacon, PhD,
Richard E Needham,
Richard Heath Coats,
Robert D Tollefsen,
Robert J Maffei,
Robert J Martin,
Rochelle K Kimmel,
Roger F Zabinski,
Ruark Lanham,
Ruben C Ayala, PharmD,
Russell J Glapion,
Saied A Asbagh,
Sandra A Hughes,
Sherri N Rohlf, MD,
Sidney B Priesmeyer,
Simone E Pitts,
Steven C Madzo,
Steven L Carter,
Steven M Weinman,
Susan F Laska, MS,
Susan M Jackson,
Susanne M Richardson, MSc RAC ELS,
Tania E Vizcaino,
Tara G Bizjak,
Tara R Gooen,
Teresa I Navas,
Terri L Dodds,
Thai D Truong,
Thomas J Arista,
Thomas R Withers,
Timothy T Kapsala,
Torrance J Slayton,
Uttaniti Limchumroon (Tom),
Vlada Matusovsky,
Walden H Lee,
Wayne E Seifert,
Yvesna C Blaise,
Zhongren Wu
Wayne T Smith's Documents
Publish Date | Document Type | Title |
---|---|---|
July, 2003 | EIR | MSD Organon - EIR, 2003-07-11 |
October, 2001 | FDA 483 | Ortho-McNeil Pharmaceutical Inc - Form 483, 2001-10-05 |
March, 2000 | FDA 483 Response | Sybron Chemical Div - Form 483R, 2000-04-19 |
July, 2003 | FDA 483 Response | N.V. Organon - Form 483R, 2003-11-04 |
March, 2004 | EIR | SICOR Societa' Italiana Corticosteroidi s.r.l. - EIR, 2004-04-14 |
July, 2003 | EIR | N. V. Organon - EIR, 2003-07-18 |
March, 2000 | FDA 483 | Sybron Chemical Div - Form 483, 2000-03-10 |
March, 2006 | EIR | Novetide Ltd. - EIR, 2006-03-15 |
March, 2000 | EIR | Sybron Chemical Div - EIR, 2000-03-10 |
March, 2004 | EIR | Chemi SpA - EIR, 2004-05-04 |
July, 2003 | EIR | N.V. Organon - EIR, 2003-07-17 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more